| Bryan Scott Hauser, MD | |
|
655 Main St, Va Clinic, Saco, ME 04072 | |
| (207) 294-3100 | |
| (207) 286-3709 |
| Full Name | Bryan Scott Hauser |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 655 Main St, Saco, Maine |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104838184 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 11699 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Bryan Scott Hauser, MD 62 Storer St, Kennebunk, ME 04043 Ph: (207) 985-9129 | Bryan Scott Hauser, MD 655 Main St, Va Clinic, Saco, ME 04072 Ph: (207) 294-3100 |
News Archive
German researchers have identified four biomarkers that correctly determine malignancy of urinary bladder cancers and contribute to the accurate prediction of patient outcomes. Their results are published in the September issue of The Journal of Molecular Diagnostics.
Researchers from the Polytechnic University of Catalonia (UPC) and the University of Lovaina (UCL), in Belgium, have presented a technique that, using two video cameras to capture human movement, makes it possible to recognize body movements and display them in three dimension on a computer, according to the journal Multimedia Tools & Applications. The method can be applied to the development of interactive video games in which gestures are made with the hands and feet.
Emisphere Technologies, Inc. today announced that Novo Nordisk has initiated its first Phase I clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a $2 million payment to Emisphere, whose proprietary Eligen® Technology is used in the formulation of NN9924.
Helix BioMedix, Inc., a developer of bioactive peptides, announced that the Company entered into an agreement with RubyDerm Bio, Inc. under which RubyDerm will assume responsibility, on an exclusive basis, for the distribution of certain of Helix BioMedix's branded prestige skin care products to spas, beauty stores, hospitals, clinics, physicians, and consumers in South Korea, China and Japan.
Dana-Farber Cancer Institute and the Sanford-Burnham Medical Research Institute have signed a license agreement with Genentech, a wholly owned member of the Roche group, and Roche, that grants the companies exclusive rights to manufacture, develop and market human monoclonal antibodies to treat and protect against group 1 influenza viruses.
› Verified 1 days ago